Horm Metab Res 2020; 52(05): 336-339
DOI: 10.1055/a-1149-9347
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

GHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity

1   School of Basic Pharmaceutical and Toxicological Sciences, University of Louisiana Monroe, Monroe, LA, USA
,
Mohammad S. Akhter
1   School of Basic Pharmaceutical and Toxicological Sciences, University of Louisiana Monroe, Monroe, LA, USA
,
Mohammad A. Uddin
1   School of Basic Pharmaceutical and Toxicological Sciences, University of Louisiana Monroe, Monroe, LA, USA
,
Khadeja-Tul Kubra
1   School of Basic Pharmaceutical and Toxicological Sciences, University of Louisiana Monroe, Monroe, LA, USA
,
Andrew V. Schally
2   Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, University of Miami, Miami, FL, USA
› Author Affiliations
Funding: The study was supported by the R & D, Research Competitiveness Subprogram (RCS) of the Louisiana Board of Regents through the Board of Regents Support Fund (LEQSF(2019-22)-RD-A-26) (NB), the Faculty Research Support Program from the College of Pharmacy in ULM (NB), and the Medical Research Service of the Department of Veterans Affairs and University of Miami Miller School of Medicine (AVS).
Further Information

Publication History

received 17 February 2020

Publication Date:
13 May 2020 (online)

Abstract

Growth hormone releasing hormone is a hypothalamic neuropeptide, which regulates the release of growth hormone from the anterior pituitary gland. Growth hormone releasing hormone antagonists are anticancer agents, associated with strong anti-inflammatory activities. In the present study, we investigated the effects of the GHRH antagonist MIA-602 in the integrity of the brain microvascular endothelium in vitro. Our observations suggest that MIA-602 protects against the H2O2-induced breakdown of the brain endothelium and enhances its integrity by inducing P53, deactivating cofilin, and suppressing the RhoA inflammatory pathway. Thus, GHRH antagonists may offer an exciting possibility for the treatment of pathologies related to the blood brain barrier dysfunction, including the Parkinson’s and Alzheimer’s diseases.

 
  • References

  • 1 Liang WC, Ren JL, Yu QX. et al. Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation. Proc Natl Acad Sci USA 2020; 117: 6067-60764
  • 2 Barabutis N, Siejka A, Schally AV. Growth hormone releasing hormone induces the expression of nitric oxide synthase. J Cell Mol Med 2011; 15: 1148-1155
  • 3 Barabutis N, Schally AV. Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line. Proc Natl Acad Sci USA 2008; 105: 20470-20475
  • 4 Recinella L, Chiavaroli A, Orlando G. et al. Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice. Sci Rep 2020; 10: 732
  • 5 Barabutis N, Schally AV, Siejka A. P53, GHRH, inflammation and cancer. EBioMedicine 2018; 37: 557-562
  • 6 Akhter MS, Uddin MA, Kubra KT. et al. P53-induced reduction of lipid peroxidation supports brain microvascular endothelium integrity. J Pharmacol Sci 2019; 141: 83-85
  • 7 Jaeger LB, Banks WA, Varga JL. et al. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc Natl Acad Sci USA 2005; 102: 12495-12500
  • 8 Anasooya Shaji C, Robinson BD, Yeager A. et al. The tri-phasic role of hydrogen peroxide in blood-brain barrier endothelial cells. Sci Rep 2019; 9: 133
  • 9 Mantovani G, Treppiedi D, Giardino E. et al. Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. Endocr Relat Cancer 2019; 26: R95-R108
  • 10 Barabutis N, Dimitropoulou C, Gregory B. et al. Wild-type p53 enhances endothelial barrier function by mediating RAC1 signalling and RhoA inhibition. J Cell Mol Med 2018; 22: 1792-1804
  • 11 Pronk MCA, van Bezu JSM, van Nieuw Amerongen GP. et al. RhoA, RhoB and RhoC differentially regulate endothelial barrier function. Small GTPases 2019; 10: 466-484
  • 12 Barabutis N. P53 in RhoA regulation. Cytoskeleton (Hoboken) 2020; DOI: 10.1002/cm.21604.
  • 13 Aghajanian A, Wittchen ES, Campbell SL. et al. Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif. PLoS One 2009; 4: e8045
  • 14 Zarandi M, Cai R, Kovacs M. et al. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. Peptides 2017; 89: 60-70
  • 15 Kubra KT, Uddin MA, Akhter MS. et al. Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells. Cell Signal 2020; 67: 109500
  • 16 Uddin MA, Akhter MS, Siejka A. et al. P53 supports endothelial barrier function via APE1/Ref1 suppression. Immunobiology 2019; 224: 532-538
  • 17 Barabutis N, Dimitropoulou C, Birmpas C. et al. p53 protects against LPS-induced lung endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2015; 308: L776-L787
  • 18 Uddin MA, Akhter MS, Singh SS. et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers 2019; 7: 1669989
  • 19 Sweeney MD, Zhao Z, Montagne A. et al. Blood-brain barrier: From physiology to disease and back. Physiol Rev 2019; 99: 21-78
  • 20 Barabutis N. Growth hormone releasing hormone in the unfolded protein response context. Endocrine 2020; 67: 291-293